• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一种由藻类制成的新冠病毒受体结合域在小鼠中具有免疫原性。

An Algae-Made RBD from SARS-CoV-2 Is Immunogenic in Mice.

作者信息

Govea-Alonso Dania O, Malla Ashwini, Bolaños-Martínez Omayra C, Vimolmangkang Sornkanok, Rosales-Mendoza Sergio

机构信息

Laboratorio de Biofarmacéuticos Recombinantes, Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, Av. Dr. Manuel Nava 6, San Luis Potosi 78210, Mexico.

Sección de Biotecnología, Centro de Investigación en Ciencias de la Salud y Biomedicina, Universidad Autónoma de San Luis Potosí, Av. Sierra Leona 550, Lomas 2ª Sección, San Luis Potosi 78210, Mexico.

出版信息

Pharmaceuticals (Basel). 2022 Oct 21;15(10):1298. doi: 10.3390/ph15101298.

DOI:10.3390/ph15101298
PMID:36297410
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9607479/
Abstract

Despite the current advances in global vaccination against SARS-CoV-2, boosting is still required to sustain immunity in the population, and the induction of sterilizing immunity remains as a pending goal. Low-cost oral immunogens could be used as the basis for the design of affordable and easy-to-administer booster vaccines. Algae stand as promising platforms to produce immunogens at low cost, and it is possible to use them as oral delivery carriers since they are edible (not requiring complex purification and formulation processes). Herein, a -made SARS-CoV-2 RBD was evaluated as an oral immunogen in mice to explore the feasibility of developing an oral algae-based vaccine. The test immunogen was stable in freeze-dried algae biomass and able to induce, by the oral route, systemic and mucosal humoral responses against the spike protein at a similar magnitude to those induced by injected antigen plus alum adjuvant. IgG subclass analysis revealed a Th2-bias response which lasted over 4 months after the last immunization. The induced antibodies showed a similar reactivity against either Delta or Omicron variants. This study represents a step forward in the development of oral vaccines that could accelerate massive immunization.

摘要

尽管目前全球针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的疫苗接种取得了进展,但仍需要加强免疫以维持人群免疫力,而诱导无菌免疫仍是一个有待实现的目标。低成本口服免疫原可作为设计经济实惠且易于给药的加强疫苗的基础。藻类是有望低成本生产免疫原的平台,并且由于它们可食用(不需要复杂的纯化和制剂工艺),因此有可能将它们用作口服递送载体。在此,对一种人工合成的SARS-CoV-2受体结合域(RBD)作为小鼠口服免疫原进行了评估,以探索开发基于藻类的口服疫苗的可行性。测试免疫原在冻干的藻类生物质中稳定,并且通过口服途径能够诱导针对刺突蛋白的全身性和黏膜体液反应,其程度与注射抗原加明矾佐剂诱导的反应相似。IgG亚类分析显示为Th2偏向性反应,在最后一次免疫后持续超过4个月。诱导产生的抗体对德尔塔或奥密克戎变体显示出相似的反应性。这项研究代表了口服疫苗开发的一个进步,有望加速大规模免疫接种。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1c5/9607479/2056ee5eba40/pharmaceuticals-15-01298-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1c5/9607479/1f5d96e4e406/pharmaceuticals-15-01298-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1c5/9607479/7d992bad4e7b/pharmaceuticals-15-01298-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1c5/9607479/a1a50421ffc3/pharmaceuticals-15-01298-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1c5/9607479/ef63ccf5b0ea/pharmaceuticals-15-01298-g004a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1c5/9607479/41a41078f28d/pharmaceuticals-15-01298-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1c5/9607479/7250704eaf45/pharmaceuticals-15-01298-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1c5/9607479/2056ee5eba40/pharmaceuticals-15-01298-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1c5/9607479/1f5d96e4e406/pharmaceuticals-15-01298-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1c5/9607479/7d992bad4e7b/pharmaceuticals-15-01298-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1c5/9607479/a1a50421ffc3/pharmaceuticals-15-01298-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1c5/9607479/ef63ccf5b0ea/pharmaceuticals-15-01298-g004a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1c5/9607479/41a41078f28d/pharmaceuticals-15-01298-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1c5/9607479/7250704eaf45/pharmaceuticals-15-01298-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f1c5/9607479/2056ee5eba40/pharmaceuticals-15-01298-g007.jpg

相似文献

1
An Algae-Made RBD from SARS-CoV-2 Is Immunogenic in Mice.一种由藻类制成的新冠病毒受体结合域在小鼠中具有免疫原性。
Pharmaceuticals (Basel). 2022 Oct 21;15(10):1298. doi: 10.3390/ph15101298.
2
Production and Purification of LTB-RBD: A Potential Antigen for Mucosal Vaccine Development against SARS-CoV-2.LTB-RBD的生产与纯化:一种用于开发抗SARS-CoV-2黏膜疫苗的潜在抗原
Vaccines (Basel). 2022 Oct 20;10(10):1759. doi: 10.3390/vaccines10101759.
3
Intranasal Administration of RBD Nanoparticles Confers Induction of Mucosal and Systemic Immunity against SARS-CoV-2.鼻内给药RBD纳米颗粒可诱导针对SARS-CoV-2的黏膜和全身免疫。
Vaccines (Basel). 2021 Jul 9;9(7):768. doi: 10.3390/vaccines9070768.
4
An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.鼻内注射慢病毒加强针可增强正在减弱的、由mRNA疫苗诱导产生的、针对肺黏膜的SARS-CoV-2免疫力。
Mol Ther. 2022 Sep 7;30(9):2984-2997. doi: 10.1016/j.ymthe.2022.04.016. Epub 2022 Apr 27.
5
RBD-VLP Vaccines Adjuvanted with Alum or SWE Protect K18-hACE2 Mice against SARS-CoV-2 VOC Challenge.铝佐剂或 SWE 增强的 RBD-VLP 疫苗可保护 K18-hACE2 小鼠免受 SARS-CoV-2 VOC 挑战。
mSphere. 2022 Aug 31;7(4):e0024322. doi: 10.1128/msphere.00243-22. Epub 2022 Aug 15.
6
A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.一种糖基化 RBD 蛋白诱导针对奥密克戎和其他变体的增强型中和抗体,提高对 SARS-CoV-2 感染的保护作用。
J Virol. 2022 Sep 14;96(17):e0011822. doi: 10.1128/jvi.00118-22. Epub 2022 Aug 16.
7
Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant.原型株和奥密克戎 RBD mRNA 疫苗对奥密克戎变异株中和效力。
Front Immunol. 2022 Jun 30;13:908478. doi: 10.3389/fimmu.2022.908478. eCollection 2022.
8
Humoral immune response to authentic circulating severe acute respiratory syndrome coronavirus 2 variants elicited by booster vaccination with distinct receptor-binding domain subunits in mice.体液免疫应答对用不同受体结合域亚单位增强接种后循环中的真实严重急性呼吸综合征冠状病毒 2 变体的小鼠
J Med Virol. 2022 Sep;94(9):4533-4538. doi: 10.1002/jmv.27882. Epub 2022 Jun 3.
9
Correlation Analysis of Anti-SARS-CoV-2 RBD IgG and Neutralizing Antibody against SARS-CoV-2 Omicron Variants after Vaccination.接种疫苗后抗SARS-CoV-2 RBD IgG与针对SARS-CoV-2奥密克戎变异株的中和抗体的相关性分析
Diagnostics (Basel). 2022 May 25;12(6):1315. doi: 10.3390/diagnostics12061315.
10
The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.科兴新冠疫苗第三针诱导广泛而有效的适应性免疫应答,能识别 SARS-CoV-2 德尔塔和奥密克戎变异株。
Emerg Microbes Infect. 2022 Dec;11(1):1524-1536. doi: 10.1080/22221751.2022.2081614.

引用本文的文献

1
Advances and challenges in poliomyelitis vaccines: a comprehensive review of development, production, and global deployment.脊髓灰质炎疫苗的进展与挑战:对其研发、生产及全球部署的全面综述
Front Public Health. 2025 Jul 16;13:1611028. doi: 10.3389/fpubh.2025.1611028. eCollection 2025.
2
Protein Expression Platforms and the Challenges of Viral Antigen Production.蛋白质表达平台与病毒抗原生产的挑战
Vaccines (Basel). 2024 Nov 28;12(12):1344. doi: 10.3390/vaccines12121344.
3
Green Biologics: Harnessing the Power of Plants to Produce Pharmaceuticals.

本文引用的文献

1
Considerations for Novel COVID-19 Mucosal Vaccine Development.新型新冠病毒黏膜疫苗研发的考量因素
Vaccines (Basel). 2022 Jul 23;10(8):1173. doi: 10.3390/vaccines10081173.
2
Current Status and Perspective on the Use of Viral-Based Vectors in Eukaryotic Microalgae.真核微藻中病毒载体的应用现状与展望。
Mar Drugs. 2022 Jun 29;20(7):434. doi: 10.3390/md20070434.
3
Boosting of SARS-CoV-2 immunity in nonhuman primates using an oral rhabdoviral vaccine.口服弹状病毒疫苗增强非人类灵长类动物的 SARS-CoV-2 免疫力。
绿色生物制品:利用植物生产药物。
Int J Mol Sci. 2023 Dec 17;24(24):17575. doi: 10.3390/ijms242417575.
4
Oral Delivery of mRNA Vaccine by Plant-Derived Extracellular Vesicle Carriers.植物源细胞外囊泡载体的 mRNA 疫苗口服递送。
Cells. 2023 Jul 11;12(14):1826. doi: 10.3390/cells12141826.
5
Comparing the Ability of Secretory Signal Peptides for Heterologous Expression of Anti-Lipopolysaccharide Factor 3 in .比较分泌信号肽在.中异源表达抗脂多糖因子 3 的能力。
Mar Drugs. 2023 Jun 4;21(6):346. doi: 10.3390/md21060346.
Vaccine. 2022 Apr 1;40(15):2342-2351. doi: 10.1016/j.vaccine.2021.12.063. Epub 2022 Jan 10.
4
Attacking the Intruder at the Gate: Prospects of Mucosal Anti SARS-CoV-2 Vaccines.在源头阻击入侵者:黏膜抗SARS-CoV-2疫苗的前景
Pathogens. 2022 Jan 19;11(2):117. doi: 10.3390/pathogens11020117.
5
Oral subunit SARS-CoV-2 vaccine induces systemic neutralizing IgG, IgA and cellular immune responses and can boost neutralizing antibody responses primed by an injected vaccine.口服亚单位 SARS-CoV-2 疫苗可诱导全身中和 IgG、IgA 和细胞免疫应答,并能增强已接种疫苗产生的中和抗体应答。
Vaccine. 2022 Feb 16;40(8):1098-1107. doi: 10.1016/j.vaccine.2022.01.025. Epub 2022 Jan 19.
6
Expression of SARS-CoV-2 Spike Protein Receptor Binding Domain on Recombinant on Spore Surface: A Potential COVID-19 Oral Vaccine Candidate.重组孢子表面的严重急性呼吸综合征冠状病毒2刺突蛋白受体结合域的表达:一种潜在的COVID-19口服疫苗候选物。
Vaccines (Basel). 2021 Dec 21;10(1):2. doi: 10.3390/vaccines10010002.
7
Safety, immunogenicity, and protection provided by unadjuvanted and adjuvanted formulations of a recombinant plant-derived virus-like particle vaccine candidate for COVID-19 in nonhuman primates.在非人灵长类动物中,一种新型冠状病毒重组植物源性病毒样颗粒候选疫苗的无佐剂和佐剂制剂的安全性、免疫原性和保护作用。
Cell Mol Immunol. 2022 Feb;19(2):222-233. doi: 10.1038/s41423-021-00809-2. Epub 2022 Jan 5.
8
Recombinant production of a functional SARS-CoV-2 spike receptor binding domain in the green algae Chlamydomonas reinhardtii.在绿藻莱茵衣藻中重组表达具有功能的 SARS-CoV-2 刺突受体结合域。
PLoS One. 2021 Nov 18;16(11):e0257089. doi: 10.1371/journal.pone.0257089. eCollection 2021.
9
Oral Vaccination Protects Against Severe Acute Respiratory Syndrome Coronavirus 2 in a Syrian Hamster Challenge Model.口服疫苗可预防叙利亚仓鼠挑战模型中的严重急性呼吸综合征冠状病毒 2。
J Infect Dis. 2022 Jan 5;225(1):34-41. doi: 10.1093/infdis/jiab561.
10
Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis.新型冠状病毒肺炎疫苗的有效性、免疫原性和安全性的系统评价和荟萃分析。
Front Immunol. 2021 Oct 11;12:714170. doi: 10.3389/fimmu.2021.714170. eCollection 2021.